Literature DB >> 15678691

Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns.

D Dragovic1, J L Rosenstock, S J Wahl, G Panagopoulos, M V DeVita, M F Michelis.   

Abstract

BACKGROUND: Idiopathic focal segmental glomerulosclerosis (FSGS) is one of the leading causes of the nephrotic syndrome in adults and an important cause of end-stage renal disease. Its incidence has dramatically increased in the last two decades and it is especially prevalent among black patients. The trend of FSGS incidence has not been reported beyond 1997.
METHODS: We retrospectively reviewed all renal biopsies performed at our institution between 1986 and 2002 and identified patients with diagnoses consistent with primary glomerulopathy (PG), which included: minimal-change disease (MCD), idiopathic focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MGN), IgA nephropathy (IgA), membrano-proliferative glomerulonephritis (MPGN) and mesangioproliferative glomerulonephritis. Patients with possible secondary causes for their renal disease were excluded. Clinical data at the time of biopsy and follow-up data were collected and analyzed.
RESULTS: During the period from January 1986-December 2002, 299 renal biopsies were performed and 132 patients were diagnosed with PG. FSGS was the most common form of PG representing 37.8% of all PG followed by IgA 27.3%, MGN 16.6% and MCD 9.1%. Among FSGS patients 59% were females, 64% had nephrotic range proteinuria and 54% had the nephrotic syndrome. Mean serum creatinine was 2.0 +/- 0.2 mg/dl and mean protein excretion was 6.1 +/- 1.0 g/day. The incidence of FSGS increased from 19.3% (1986-1991) and 16.6% (1992-1997) to 58.5% in the period from 2002. The increase occurred among black and Hispanic patients (33.3-79.2%) as well as white patients (12.5-51.5%). Black and Hispanic patients with PG presented for renal biopsy at a significantly younger age than white patients (p = 0.003), with mean age 37.5 +/- 2.0 years vs. 50.3 +/- 1.8 years. White FSGS patients were significantly older than white non-FSGS patients (mean age 56.4 +/- 3.2 years vs. 48.0 +/- 2.0 years, p = 0.03). Black and Hispanic FSGS patients were also older when compared to their non-FSGS counter-parts (mean age 40.6 +/- 2.8 years vs. 32.1 +/- 2.0 years, p = 0.04). When patients were stratified by age (< 45 years and > or = 45 years), FSGS was the most common diagnosis in both age groups among black and Hispanic patients (55.1% and 88.8%) but only among older white patients (36.2%).
CONCLUSIONS: The incidence of FSGS as a proportion of PG in our population has increased markedly in the most recent time period analyzed (1998-2002). The increase has occurred among both white and black and Hispanic patients. We also found that FSGS was most prevalent in patients > or = 45 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678691     DOI: 10.5414/cnp63001

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  33 in total

1.  Growth-dependent podocyte failure causes glomerulosclerosis.

Authors:  Akihiro Fukuda; Mahboob A Chowdhury; Madhusudan P Venkatareddy; Su Q Wang; Ryuzoh Nishizono; Tsukasa Suzuki; Larysa T Wickman; Jocelyn E Wiggins; Timothy Muchayi; Diane Fingar; Kerby A Shedden; Ken Inoki; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 10.121

2.  A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS.

Authors:  Gentzon Hall; Rasheed A Gbadegesin; Peter Lavin; Guanghong Wu; Yangfan Liu; Edwin C Oh; Liming Wang; Robert F Spurney; Jason Eckel; Thomas Lindsey; Alison Homstad; Andrew F Malone; Paul J Phelan; Andrey Shaw; David N Howell; Peter J Conlon; Nicholas Katsanis; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

3.  Structure of the receptor-activated human TRPC6 and TRPC3 ion channels.

Authors:  Qinglin Tang; Wenjun Guo; Li Zheng; Jing-Xiang Wu; Meng Liu; Xindi Zhou; Xiaolin Zhang; Lei Chen
Journal:  Cell Res       Date:  2018-04-26       Impact factor: 25.617

4.  Histopathologic patterns of adult renal disease in Kermanshah, Iran: A 6-year review of two referral centers.

Authors:  Keykhosro Mardanpour; Mahtab Rahbar
Journal:  Caspian J Intern Med       Date:  2013

5.  Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.

Authors:  Debbie S Gipson; Howard Trachtman; Frederick J Kaskel; Milena K Radeva; Jennifer Gassman; Tom H Greene; Marva M Moxey-Mims; Ronald J Hogg; Sandra L Watkins; Richard N Fine; John P Middleton; V M Vehaskari; Susan L Hogan; Suzzane Vento; Patti A Flynn; Leslie M Powell; June L McMahan; Norman Siegel; Aaron L Friedman
Journal:  Kidney Int       Date:  2010-12-22       Impact factor: 10.612

6.  FSGS as an Adaptive Response to Growth-Induced Podocyte Stress.

Authors:  Ryuzoh Nishizono; Masao Kikuchi; Su Q Wang; Mahboob Chowdhury; Viji Nair; John Hartman; Akihiro Fukuda; Larysa Wickman; Jeffrey B Hodgin; Markus Bitzer; Abhijit Naik; Jocelyn Wiggins; Matthias Kretzler; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2017-07-18       Impact factor: 10.121

7.  Renal biopsy findings in Iran: case series report from a referral kidney center.

Authors:  Shahrzad Ossareh; Mojgan Asgari; Ezatollah Abdi; Hosein Nejad-Gashti; Yousef Ataipour; Sasan Aris; Fereidoon Proushani; Ghodratollah Ghorbani; Fatemeh Hayati; Ahad J Ghods
Journal:  Int Urol Nephrol       Date:  2010-01-06       Impact factor: 2.370

Review 8.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

9.  The spectrum of glomerular diseases on renal biopsy: data from a single tertiary center in oman.

Authors:  Dawood Al Riyami
Journal:  Oman Med J       Date:  2013-05

10.  An unexpected presentation: minimal change disease in an adult with treatment-naïve hepatitis C.

Authors:  Audrey L Stokes; Tarek Alhamad; Catherine S Abendroth; Hosam A Farag; Navin Verma
Journal:  Int Urol Nephrol       Date:  2012-09-22       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.